<p>中央太平洋银行信托部门在最近向美国证券交易委员会提交的 13F 文件中表示，在第三季度将其在 Cencora, Inc.（纽约证券交易所代码：COR - 免费报告）的持股增加了 654.6%。该基金在季度内购买了额外的 3,633 股后，持有该公司 4,188 股股票。根据其最近的 SEC 文件，中央太平洋银行信托部门在 Cencora 的持股价值为 1,309,000 美元。</p>
<ul>
<li>在下跌市场中，标准普尔 500 指数的前三大赢家</li>
</ul>
<p>其他机构投资者和对冲基金最近也买卖了该公司的股票。Kovitz 投资集团合伙公司在第一季度将其在 Cencora 的持仓提高了 9.3%。Kovitz 投资集团合伙公司目前持有 3,513 股该公司的股票，价值 977,000 美元，此前在上个季度购买了额外的 299 股。Ethic Inc.在第一季度将其在 Cencora 的股份提高了 2.4%。Ethic Inc.目前持有 9,769 股该公司的股票，价值 2,710,000 美元，此前在上个季度收购了额外的 233 股。Steward Partners 投资顾问公司在第一季度将其在 Cencora 的股份提高了 1.0%。Steward Partners 投资顾问公司目前持有 53,475 股该公司的股票，价值 14,871,000 美元，此前在上个季度收购了 507 股。Aviso Financial Inc.在第一季度将其在 Cencora 的股份提高了 17.5%。Aviso Financial Inc.目前持有 8,769 股该公司的股票，价值 2,439,000 美元，此前在上个季度购买了 1,305 股。最后，Aptus Capital Advisors LLC 在第一季度将其在 Cencora 的股份提高了 39.7%。Aptus Capital Advisors LLC 目前持有 3,699 股该公司的股票，价值 1,029,000 美元，此前在上个季度购买了 1,052 股。机构投资者和对冲基金持有该公司 97.52% 的股票。</p>
<h2>内部活动</h2>
<p>在其他新闻中，首席执行官 Robert P. Mauch 于 11 月 18 日星期二出售了 5,096 股 Cencora 股票。该股票以平均价格 366.64 美元出售，总交易额为 1,868,397.44 美元。交易后，首席执行官持有 65,746 股公司股票，价值 24,105,113.44 美元。此次交易使其持仓减少了 7.19%。该交易已在向 SEC 提交的文件中披露，相关文件可在此链接查看。内部人士在过去九十天内出售了 15,290 股公司股票，价值 5,012,227 美元。10.80% 的股票由公司内部人士持有。</p>
<h2>Cencora 股票上涨 1.3%</h2>
<ul>
<li>Walgreens 股票反弹：WBA 可能成为强劲买入的四个理由</li>
</ul>
<p>Cencora 股票在星期二开盘价为 350.33 美元。Cencora, Inc.的 52 周低点为 223.92 美元，52 周高点为 377.54 美元。该公司的债务与股本比率为 4.32，流动比率为 0.90，速动比率为 0.55。该公司的市值为 679.6 亿美元，市盈率为 44.07，PEG 比率为 1.64，贝塔值为 0.63。该公司的 50 日简单移动平均线为 344.19 美元，200 日简单移动平均线为 311.91 美元。</p>
<p>Cencora（纽约证券交易所代码：COR - 获取免费报告）最近于 11 月 5 日星期三发布了其财报。该公司报告本季度每股收益为 3.84 美元，超出市场共识预期的 3.79 美元，超出 0.05 美元。Cencora 的净利润率为 0.48%，股本回报率为 227.15%。该公司本季度的收入为 837.3 亿美元，而分析师预期为 833.6 亿美元。去年同期，该公司每股收益为 3.34 美元。与去年同期相比，该公司的季度收入增长了 5.9%。Cencora 已将其 2026 财年的指导目标设定为每股收益 17.450-17.75 美元。整体来看，卖方分析师预计 Cencora, Inc.在当前年度将发布每股收益 15.37 美元。</p>
<h2>Cencora 增加股息</h2>
<ul>
<li>Teva Pharma 是重新崛起的仿制药投资的最佳选择</li>
</ul>
<p>该公司还最近宣布了季度股息，该股息于 12 月 1 日星期一支付。11 月 14 日星期五的登记股东获得了 0.60 美元的股息。该股息的除息日期为 11 月 14 日星期五。这是 Cencora 之前季度股息 0.55 美元的积极变化。这相当于每年 2.40 美元的股息，收益率为 0.7%。Cencora 目前的派息比率为 30.19%。</p>
<h2>分析师设定新的价格目标</h2>
<p>COR 已成为几份研究分析师报告的主题。瑞银集团在 11 月 7 日的研究报告中将 Cencora 的目标价格从 380.00 美元上调至 415.00 美元，并给予该股票 “买入” 评级。Evercore ISI 在 11 月 6 日的研究报告中将 Cencora 的目标价格设定为 400.00 美元，并给予该股票 “跑赢大盘” 评级。TD Cowen 在 11 月 10 日的报告中将 Cencora 的目标价格从 350.00 美元上调至 400.00 美元，并给予该公司 “买入” 评级。Weiss Ratings 在 12 月 8 日的研究报告中重申了对 Cencora 股票的 “持有（c+）” 评级。最后，华尔街 Zen 在 11 月 28 日的研究报告中将 Cencora 的评级从 “买入” 下调至 “持有”。一位投资分析师对该股票给予了强烈买入评级，八位分析师给予了买入评级，四位分析师给予了持有评级。根据 MarketBeat.com 的数据，Cencora 目前的平均评级为 “适度买入”，平均目标价格为 373.50 美元。</p>
<p><strong>获取我们关于 Cencora 的最新研究报告</strong></p>
<h2>Cencora 简介</h2>
<p>（免费报告）</p>
<p>Cencora, Inc. 负责药品的采购和分销。该公司的美国医疗解决方案部门向急性护理医院和医疗系统、独立和连锁零售药房、邮购药房、医疗诊所、长期护理和替代场所药房以及其他客户分销药品、非处方医疗产品、家庭医疗用品和设备及相关服务；提供药房管理、人员配置和其他咨询服务；向零售和机构医疗提供者提供供应管理软件；向各种机构和零售医疗提供者提供包装解决方案；提供临床试验支持、产品上市后和商业化支持服务；为生物技术和制药制造商提供数据分析、结果研究和其他服务；向伴侣动物和生产动物市场提供药品、疫苗、驱虫剂、诊断产品、微饲料成分及其他产品；以及向制造商提供销售团队服务。</p>
<h2>另见</h2>
<ul>
<li>五只我们更看好的股票，胜过 Cencora</li>
<li>什么是 MarketRank™？如何使用它</li>
<li>ServiceNow 的 70 亿美元赌注：恐慌还是机会？</li>
<li>FAANG 股票是什么？它们是好的投资吗？</li>
<li>戴尔和惠普正在涨价——投资者应该注意</li>
<li>3 只值得长期持有的 REITs</li>
<li>为什么 DLocal 是 2026 年值得关注的顶级新兴市场金融科技股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNPUg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNPUg"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Cencora 吗？</h2>
<p>在你考虑 Cencora 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Cencora 并不在名单上。</p>
<p>虽然 Cencora 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

<p>中央太平洋银行信托部门在第三季度将其在 Cencora, Inc.的持股增加了 654.6%，额外购入了 3,633 股，目前总持股达到 4,188 股，市值为 1,309,000 美元。其他机构投资者也增加了在 Cencora 的持仓。该公司的股票开盘价为 350.33 美元，市值为 679.6 亿美元。Cencora 报告本季度每股收益为 3.84 美元，超出预期，并将季度股息提高至每股 0.60 美元</p>

<p>Central Pacific Bank Trust Division raised its holdings in Cencora, Inc. (NYSE:COR - Free Report) by 654.6% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 4,188 shares of the company's stock after purchasing an additional 3,633 shares during the quarter. Central Pacific Bank Trust Division's holdings in Cencora were worth $1,309,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>中央太平洋银行信托部门在最近向美国证券交易委员会提交的 13F 文件中表示，在第三季度将其在 Cencora, Inc.（纽约证券交易所代码：COR - 免费报告）的持股增加了 654.6%。该基金在季度内购买了额外的 3,633 股后，持有该公司 4,188 股股票。根据其最近的 SEC 文件，中央太平洋银行信托部门在 Cencora 的持股价值为 1,309,000 美元。</p>
</div><ul>
<li>Top 3 S&amp;P 500 Winners in a Losing Market</li>
</ul>
<div class="lb-trans"><ul>
<li>在下跌市场中，标准普尔 500 指数的前三大赢家</li>
</ul>
</div><p>Other institutional investors and hedge funds also recently bought and sold shares of the company. Kovitz Investment Group Partners LLC lifted its position in Cencora by 9.3% during the 1st quarter. Kovitz Investment Group Partners LLC now owns 3,513 shares of the company's stock worth $977,000 after buying an additional 299 shares in the last quarter. Ethic Inc. raised its stake in shares of Cencora by 2.4% in the first quarter. Ethic Inc. now owns 9,769 shares of the company's stock worth $2,710,000 after acquiring an additional 233 shares during the last quarter. Steward Partners Investment Advisory LLC raised its stake in shares of Cencora by 1.0% in the first quarter. Steward Partners Investment Advisory LLC now owns 53,475 shares of the company's stock worth $14,871,000 after acquiring an additional 507 shares during the last quarter. Aviso Financial Inc. lifted its position in shares of Cencora by 17.5% during the first quarter. Aviso Financial Inc. now owns 8,769 shares of the company's stock worth $2,439,000 after purchasing an additional 1,305 shares in the last quarter. Finally, Aptus Capital Advisors LLC grew its stake in shares of Cencora by 39.7% during the first quarter. Aptus Capital Advisors LLC now owns 3,699 shares of the company's stock valued at $1,029,000 after purchasing an additional 1,052 shares during the last quarter. Institutional investors and hedge funds own 97.52% of the company's stock.</p>
<div class="lb-trans"><p>其他机构投资者和对冲基金最近也买卖了该公司的股票。Kovitz 投资集团合伙公司在第一季度将其在 Cencora 的持仓提高了 9.3%。Kovitz 投资集团合伙公司目前持有 3,513 股该公司的股票，价值 977,000 美元，此前在上个季度购买了额外的 299 股。Ethic Inc.在第一季度将其在 Cencora 的股份提高了 2.4%。Ethic Inc.目前持有 9,769 股该公司的股票，价值 2,710,000 美元，此前在上个季度收购了额外的 233 股。Steward Partners 投资顾问公司在第一季度将其在 Cencora 的股份提高了 1.0%。Steward Partners 投资顾问公司目前持有 53,475 股该公司的股票，价值 14,871,000 美元，此前在上个季度收购了 507 股。Aviso Financial Inc.在第一季度将其在 Cencora 的股份提高了 17.5%。Aviso Financial Inc.目前持有 8,769 股该公司的股票，价值 2,439,000 美元，此前在上个季度购买了 1,305 股。最后，Aptus Capital Advisors LLC 在第一季度将其在 Cencora 的股份提高了 39.7%。Aptus Capital Advisors LLC 目前持有 3,699 股该公司的股票，价值 1,029,000 美元，此前在上个季度购买了 1,052 股。机构投资者和对冲基金持有该公司 97.52% 的股票。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部活动</h2>
</div><p>In other news, CEO Robert P. Mauch sold 5,096 shares of Cencora stock in a transaction dated Tuesday, November 18th. The stock was sold at an average price of $366.64, for a total transaction of $1,868,397.44. Following the transaction, the chief executive officer owned 65,746 shares in the company, valued at $24,105,113.44. The trade was a 7.19% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders sold 15,290 shares of company stock valued at $5,012,227 in the last ninety days. 10.80% of the stock is owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他新闻中，首席执行官 Robert P. Mauch 于 11 月 18 日星期二出售了 5,096 股 Cencora 股票。该股票以平均价格 366.64 美元出售，总交易额为 1,868,397.44 美元。交易后，首席执行官持有 65,746 股公司股票，价值 24,105,113.44 美元。此次交易使其持仓减少了 7.19%。该交易已在向 SEC 提交的文件中披露，相关文件可在此链接查看。内部人士在过去九十天内出售了 15,290 股公司股票，价值 5,012,227 美元。10.80% 的股票由公司内部人士持有。</p>
</div><h2>Cencora Stock Up 1.3%</h2>
<div class="lb-trans"><h2>Cencora 股票上涨 1.3%</h2>
</div><ul>
<li>Walgreens Stock Rally: 4 Reasons WBA Could Be a Strong Buy</li>
</ul>
<div class="lb-trans"><ul>
<li>Walgreens 股票反弹：WBA 可能成为强劲买入的四个理由</li>
</ul>
</div><p>Cencora stock opened at $350.33 on Tuesday. Cencora, Inc. has a fifty-two week low of $223.92 and a fifty-two week high of $377.54. The company has a debt-to-equity ratio of 4.32, a current ratio of 0.90 and a quick ratio of 0.55. The firm has a market capitalization of $67.96 billion, a price-to-earnings ratio of 44.07, a PEG ratio of 1.64 and a beta of 0.63. The company's 50 day simple moving average is $344.19 and its 200 day simple moving average is $311.91.</p>
<div class="lb-trans"><p>Cencora 股票在星期二开盘价为 350.33 美元。Cencora, Inc.的 52 周低点为 223.92 美元，52 周高点为 377.54 美元。该公司的债务与股本比率为 4.32，流动比率为 0.90，速动比率为 0.55。该公司的市值为 679.6 亿美元，市盈率为 44.07，PEG 比率为 1.64，贝塔值为 0.63。该公司的 50 日简单移动平均线为 344.19 美元，200 日简单移动平均线为 311.91 美元。</p>
</div><p>Cencora (NYSE:COR - Get Free Report) last posted its earnings results on Wednesday, November 5th. The company reported $3.84 earnings per share for the quarter, topping the consensus estimate of $3.79 by $0.05. Cencora had a net margin of 0.48% and a return on equity of 227.15%. The company had revenue of $83.73 billion for the quarter, compared to analyst estimates of $83.36 billion. During the same period last year, the business posted $3.34 earnings per share. The business's revenue for the quarter was up 5.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. As a group, sell-side analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current year.</p>
<div class="lb-trans"><p>Cencora（纽约证券交易所代码：COR - 获取免费报告）最近于 11 月 5 日星期三发布了其财报。该公司报告本季度每股收益为 3.84 美元，超出市场共识预期的 3.79 美元，超出 0.05 美元。Cencora 的净利润率为 0.48%，股本回报率为 227.15%。该公司本季度的收入为 837.3 亿美元，而分析师预期为 833.6 亿美元。去年同期，该公司每股收益为 3.34 美元。与去年同期相比，该公司的季度收入增长了 5.9%。Cencora 已将其 2026 财年的指导目标设定为每股收益 17.450-17.75 美元。整体来看，卖方分析师预计 Cencora, Inc.在当前年度将发布每股收益 15.37 美元。</p>
</div><h2>Cencora Increases Dividend</h2>
<div class="lb-trans"><h2>Cencora 增加股息</h2>
</div><ul>
<li>Teva Pharma is the way to play the re-rise of generic drugs</li>
</ul>
<div class="lb-trans"><ul>
<li>Teva Pharma 是重新崛起的仿制药投资的最佳选择</li>
</ul>
</div><p>The firm also recently announced a quarterly dividend, which was paid on Monday, December 1st. Shareholders of record on Friday, November 14th were paid a $0.60 dividend. The ex-dividend date of this dividend was Friday, November 14th. This is a positive change from Cencora's previous quarterly dividend of $0.55. This represents a $2.40 dividend on an annualized basis and a yield of 0.7%. Cencora's payout ratio is presently 30.19%.</p>
<div class="lb-trans"><p>该公司还最近宣布了季度股息，该股息于 12 月 1 日星期一支付。11 月 14 日星期五的登记股东获得了 0.60 美元的股息。该股息的除息日期为 11 月 14 日星期五。这是 Cencora 之前季度股息 0.55 美元的积极变化。这相当于每年 2.40 美元的股息，收益率为 0.7%。Cencora 目前的派息比率为 30.19%。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新的价格目标</h2>
</div><p>COR has been the subject of several research analyst reports. UBS Group boosted their price objective on shares of Cencora from $380.00 to $415.00 and gave the stock a &#34;buy&#34; rating in a research report on Friday, November 7th. Evercore ISI set a $400.00 target price on Cencora and gave the stock an &#34;outperform&#34; rating in a research report on Thursday, November 6th. TD Cowen raised their price target on Cencora from $350.00 to $400.00 and gave the company a &#34;buy&#34; rating in a report on Monday, November 10th. Weiss Ratings reiterated a &#34;hold (c+)&#34; rating on shares of Cencora in a research report on Monday, December 8th. Finally, Wall Street Zen downgraded shares of Cencora from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research report on Friday, November 28th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, Cencora presently has an average rating of &#34;Moderate Buy&#34; and an average price target of $373.50.</p>
<div class="lb-trans"><p>COR 已成为几份研究分析师报告的主题。瑞银集团在 11 月 7 日的研究报告中将 Cencora 的目标价格从 380.00 美元上调至 415.00 美元，并给予该股票 “买入” 评级。Evercore ISI 在 11 月 6 日的研究报告中将 Cencora 的目标价格设定为 400.00 美元，并给予该股票 “跑赢大盘” 评级。TD Cowen 在 11 月 10 日的报告中将 Cencora 的目标价格从 350.00 美元上调至 400.00 美元，并给予该公司 “买入” 评级。Weiss Ratings 在 12 月 8 日的研究报告中重申了对 Cencora 股票的 “持有（c+）” 评级。最后，华尔街 Zen 在 11 月 28 日的研究报告中将 Cencora 的评级从 “买入” 下调至 “持有”。一位投资分析师对该股票给予了强烈买入评级，八位分析师给予了买入评级，四位分析师给予了持有评级。根据 MarketBeat.com 的数据，Cencora 目前的平均评级为 “适度买入”，平均目标价格为 373.50 美元。</p>
</div><p><strong>Get Our Latest Research Report on Cencora</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 Cencora 的最新研究报告</strong></p>
</div><h2>Cencora Profile</h2>
<div class="lb-trans"><h2>Cencora 简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.</p>
<div class="lb-trans"><p>Cencora, Inc. 负责药品的采购和分销。该公司的美国医疗解决方案部门向急性护理医院和医疗系统、独立和连锁零售药房、邮购药房、医疗诊所、长期护理和替代场所药房以及其他客户分销药品、非处方医疗产品、家庭医疗用品和设备及相关服务；提供药房管理、人员配置和其他咨询服务；向零售和机构医疗提供者提供供应管理软件；向各种机构和零售医疗提供者提供包装解决方案；提供临床试验支持、产品上市后和商业化支持服务；为生物技术和制药制造商提供数据分析、结果研究和其他服务；向伴侣动物和生产动物市场提供药品、疫苗、驱虫剂、诊断产品、微饲料成分及其他产品；以及向制造商提供销售团队服务。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Cencora</li>
<li>What is MarketRank™? How to Use it</li>
<li>ServiceNow’s $7 Billion Gamble: Panic or Opportunity?</li>
<li>What Are the FAANG Stocks and Are They Good Investments?</li>
<li>Dell and HP Are Raising Prices—And Investors Should Take Note</li>
<li>3 REITs to Buy and Hold for the Long Term</li>
<li>Why DLocal Is the Top Emerging Market Fintech Stock to Watch for 2026</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Cencora</li>
<li>什么是 MarketRank™？如何使用它</li>
<li>ServiceNow 的 70 亿美元赌注：恐慌还是机会？</li>
<li>FAANG 股票是什么？它们是好的投资吗？</li>
<li>戴尔和惠普正在涨价——投资者应该注意</li>
<li>3 只值得长期持有的 REITs</li>
<li>为什么 DLocal 是 2026 年值得关注的顶级新兴市场金融科技股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNPUg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=COR"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Cencora Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Cencora 吗？</h2>
</div><p>Before you consider Cencora, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Cencora 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cencora wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Cencora 并不在名单上。</p>
</div><p>While Cencora currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Cencora 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

中央太平洋银行信托部门收购了 Cencora, Inc.的 3,633 股股票，股票代码为$COR